Bnf 90 September 2025 March 2026

The British National Formulary (BNF) 90, published September 2025, is the essential resource for concise, practical, and evidence-based information on medicines. It is recognized globally by healthcare professionals who prescribe, dispense, and administer medicines. The BNF provides guidance on best practice in prescribing, including legal and ethical considerations, supporting safe and effective decision-making at the point of care. The 2025 edition includes extensive updates such as new monographs for treatments including vamorolone (Agamree®) for Duchenne muscular dystrophy, delgocitinib (Anzupgo®) for moderate-to-severe hand eczema, ublituximab (Briumvi®) for multiple sclerosis, and givinostat (Duvyzat®) also for Duchenne muscular dystrophy. Updates also cover cardiovascular disease risk assessment and prevention, guidance on the use of chloroquine during pregnancy and breastfeeding for rheumatic diseases, hormonal contraceptives for ovarian cancer prevention, and new indications and dosing for dupilumab in chronic obstructive pulmonary disease. Comprising 2016 pages and measuring 210 x 148 mm, the BNF 90 continues the tradition of being an independent formulary with rigorous content creation processes, published jointly by BMJ Group and Pharmaceutical Press, serving as a vital infrastructure element for UK and international healthcare.